Advances in new antivirals for chronic hepatitis B.
Advances in new antivirals for chronic hepatitis B.
复制标题
慢性乙型肝炎新型抗病毒药物的进展
DOI：
10.1097/cm9.0000000000001994
复制
发表时间：
2022-02-02
影响因子：
6.1
通讯作者：
Sun J
中科院分区：
文献类型：
--
作者：
Tang Y;Liang H;Zeng G;Shen S;Sun J
慢性乙肝病毒感染仍然是全球的健康负担。及时有效的抗病毒治疗对乙肝病毒感染者是有益的。使用现有的抗病毒药物，包括Negos(T)ide类似物和干扰素-α，患者可以实现病毒抑制，改善预后。但乙肝表面抗原丢失率较低。为了实现慢性乙肝患者的功能性治愈甚至完全治愈，需要开发新的抗病毒药物。本文综述了现有抗病毒药物的优缺点，重点介绍了新的抗病毒药物，包括直接作用的抗病毒药物和免疫治疗方法。
Chronic hepatitis B virus (HBV) infection remains a global health burden. Timely and effective antiviral therapy is beneficial for patients with HBV infection. With existing antiviral drugs, including nucleos(t)ide analogs and interferon-alfa, patients can achieve viral suppression with improved prognosis. However, the rate of hepatitis B surface antigen loss is low. To achieve a functional cure and even complete cure in chronic hepatitis B patients, new antivirals need to be developed. In this review, we summarized the advantages and disadvantages of existing antiviral drugs and focused on new antivirals including direct-acting antiviral drugs and immunotherapeutic approaches.